Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and Rituximab

Bone Marrow Transplantation

Volumn 27, Issue 3, 2001, Pages 329-332

  Skoda Smith, S ^a   Douglas, V K ^a   Mehta, P ^a   Graham Pole, J ^a   Wingard, J R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Anti CD20 monoclonal antibody; Peripheral blood stem cell transplantation; Post transplant lymphoproliferative disease; Severe combined immunodeficiency disease

Indexed keywords

BUSULFAN; CD3 ANTIGEN; CD34 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DOXORUBICIN; IMMUNOGLOBULIN; METHOTREXATE; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CASE REPORT; CELL COMPARTMENTALIZATION; CELL MATURATION; CHILD; CHILDHOOD CANCER; COMBINED IMMUNODEFICIENCY; DONOR; EPSTEIN BARR VIRUS; ERADICATION THERAPY; FATHER; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOIDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNITY; LYMPHOPROLIFERATIVE DISEASE; MALE; MOTHER; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PUVA; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; REMISSION INDUCTION; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 0035116244     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702792     Document Type: Article

References (16)

1. Post-transplant lymphoproliferative disorders: A morphologic, phenotypic and genotypic spectrum of disease
2. Anti-B cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation
3. Donor T cells as therapy for EBV lymphoproliferation post bone marrow transplant
4. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
5. Use of gene modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation
6. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
7. Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction
8. Gene rearrangement in B- and T-lymphoproliferative diseases detected by the polymerase chain reaction
9. The cell surface antigen and DNA content distribution of lymph nodes with reactive hyperplasia
10. Depletion of EBV-infected cells in donor marrow by counterflow elutriation
11. Transplantation
12. Therapy for transplant-related lymphoproliferative diseases
13. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation
14. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoetic stem-cell transplantation
15. Phenotypic and functional reconstitution of peripheral blood lymphocytes following T cell-depleted bone marrow transplantation from partially mismatched related donors